plasma
product
collect
accredit
blood
bank
institut
review
board
approv
ship
terumo
bct
unit
consist
recov
plasma
frozen
within
hour
collect
two
set
plasma
use
experi
preliminari
studi
limit
number
replic
perform
determin
whether
riboflavin
uv
light
treatment
inactiv
perform
use
pool
plasma
unit
n
verif
studi
use
replic
follow
individu
donor
plasma
unit
n
use
riboflavin
uv
light
process
previous
describ
briefli
ml
human
plasma
dispens
platelet
elp
illuminationstorag
bag
mix
ml
riboflavin
solut
riboflavin
sodium
chlorid
ph
terumo
bct
mixtur
inocul
viru
sampl
place
mirasol
illumin
terumo
bct
uv
treatment
plasma
unit
expos
jml
energi
viru
level
pathogen
mirasol
illumin
use
level
laboratori
fill
plasma
bag
briefli
immers
bleach
illumin
ensur
live
viru
adher
outsid
elp
bag
affect
light
transmiss
properti
elp
bag
viru
reduct
studi
perform
colorado
state
univers
preliminari
studi
ml
pool
plasma
product
riboflavin
inocul
ml
stock
plaqu
form
unit
pfu
ml
mix
sampl
obtain
held
ambient
temperatur
pretreat
sampl
treatment
riboflavin
uv
light
second
sampl
obtain
posttreat
sampl
pretreat
posttreat
sampl
serial
dilut
medium
minimum
essenti
medium
supplement
bovin
serum
albumin
viral
titer
test
duplic
use
plaqu
assay
vero
cell
neat
dilut
plate
previou
work
demonstr
plasma
cytotox
effect
vero
cell
data
shown
verif
studi
plasma
unit
riboflavin
inocul
ml
pfuml
sampl
remov
unit
treatment
measur
viru
titer
pretreat
sampl
serial
dilut
medium
dilut
test
use
plaqu
assay
vero
cell
posttreat
sampl
dilut
test
triplic
use
plaqu
assay
vero
cell
increas
assay
sensit
neat
dilut
plate
previou
work
demonstr
plasma
cytotox
effect
vero
cell
data
shown
briefli
plaqu
assay
confluent
vero
cell
monolay
grown
plate
well
inocul
ml
dilut
plasma
sampl
plate
rock
everi
minut
minut
overlaid
agaros
medium
incub
day
day
second
overlay
contain
neutral
red
ad
plaqu
count
follow
day
viru
titer
determin
base
plaqu
number
dilut
viru
use
experi
human
isol
strain
propag
vero
cell
cultur
dulbecco
modifi
eagl
medium
fetal
bovin
serum
describ
viru
stock
maintain
thaw
use
posttreat
sampl
neg
presenc
viru
limit
detect
reach
valu
limit
detect
consid
less
equal
calcul
limit
detect
theoret
limit
detect
calcul
use
follow
equat
p
lodlognv
n
lowest
number
particl
product
detect
confid
p
probabl
viru
undetect
confid
detect
viru
p
v
total
volum
treat
product
plasma
riboflavin
viru
v
volum
use
viral
enumer
volum
inoculatedwel
ml
number
replic
well
lowest
dilut
inocul
inactiv
viru
riboflavin
uv
light
evalu
repres
emerg
pathogen
caus
concern
regard
transfus
transmiss
work
perform
vitro
plaqu
assay
use
measur
infecti
viral
load
efficaci
riboflavin
uv
light
first
evalu
triplic
use
pool
plasma
sampl
tabl
mean
reduct
log
viral
titer
notabl
across
three
replic
assay
reduc
observ
viral
titer
limit
detect
log
pfuml
demonstr
efficaci
riboflavin
uv
light
pool
plasma
net
reduct
plasma
unit
n
assess
result
summar
tabl
mean
standard
deviat
reduct
viral
titer
log
like
pool
plasma
viru
titer
reduc
limit
detect
log
pfuml
six
plasma
unit
although
document
case
transfus
transmiss
one
pathogen
cite
specif
agent
concern
use
riboflavin
uv
treatment
reduc
infecti
titer
limit
detect
plasma
unit
test
mean
log
reduct
titer
exceed
european
committe
blood
transfus
recommend
state
consid
effect
process
reduc
screen
pathogen
least
studi
conduct
corman
colleagu
indic
patient
may
viral
load
log
rna
copiesml
howev
author
also
indic
viru
appear
infecti
cell
suggest
transfus
transmiss
unlik
although
observ
reduct
evalu
plasma
product
safe
assum
extend
platelet
product
basi
previou
research
use
mirasol
prt
demonstr
system
caus
minor
chang
platelet
compromis
hemostat
efficaci
platelet
transfus
howev
also
decreas
risk
diseas
improv
shelf
taken
togeth
result
studi
suggest
riboflavin
uv
light
might
abl
reduc
likelihood
transfus
transmiss
platelet
plasma
product
infecti
viru
present
blood
asymptomat
donor
pathogen
identifi
aabb
concern
blood
safeti
base
likelihood
transmiss
transfus
clinic
diseas
transfus
press
concern
relat
diseas
known
transfus
transmiss
event
sever
fatal
outcom
eg
dengu
viru
babesia
parasit
prion
target
screen
process
identifi
blood
product
contain
potenti
transmiss
pathogen
markedli
improv
overal
safeti
transfus
howev
although
rare
transfus
transmiss
even
pathogen
like
human
immunodefici
viru
hiv
still
occur
unit
set
like
africa
mani
new
hiv
case
link
target
screen
program
limit
part
increment
natur
updat
pathogen
list
knowledg
pathogen
recent
estim
known
human
pathogen
zoonot
consid
emerg
known
pathogen
concern
blood
safeti
one
estim
novel
virus
discov
year
virus
anim
target
screen
scale
econom
logist
feasibl
keep
pace
emerg
threat
blood
safeti
system
potenti
complementari
approach
blood
screen
program
may
potenti
replac
screen
assay
like
cytomegaloviru
west
nile
viru
riboflavin
uv
light
alreadi
establish
efficaci
broad
array
viral
pathogen
differ
virus
includ
influenza
hiv
west
nile
result
current
studi
support
find
riboflavin
uv
light
effect
inactiv
coronavirus
addit
broad
spectrum
envelop
nonenvelop
virus
alreadi
test
riboflavin
uv
light
effect
reduc
titer
human
plasma
product
limit
detect
use
vitro
cell
cultur
model
expand
list
pathogen
effect
reduc
technolog
addit
infecti
discov
blood
asymptomat
donor
riboflavin
uv
light
would
reduc
likelihood
transfus
transmiss
platelet
plasma
product
sd
sm
employe
terumo
bct
manufactur
technolog
describ
articl
rb
conflict
interest
declar
